|
Name |
4'-Benzyloxy Carvedilol
|
Molecular Formula | C31H32N2O5 | |
IUPAC Name* |
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-4-phenylmethoxyphenoxy)ethylamino]propan-2-ol
|
|
SMILES |
COC1=C(C=CC(=C1)OCC2=CC=CC=C2)OCCNCC(COC3=CC=CC4=C3C5=CC=CC=C5N4)O
|
|
InChI |
InChI=1S/C31H32N2O5/c1-35-30-18-24(37-20-22-8-3-2-4-9-22)14-15-28(30)36-17-16-32-19-23(34)21-38-29-13-7-12-27-31(29)25-10-5-6-11-26(25)33-27/h2-15,18,23,32-34H,16-17,19-21H2,1H3
|
|
InChIKey |
WFGLUJVTGHMGCX-UHFFFAOYSA-N
|
|
Synonyms |
4'-Benzyloxy Carvedilol; 887352-95-6; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-4-phenylmethoxyphenoxy)ethylamino]propan-2-ol; 4'-BENZYLOXY-CARVEDILOL; DTXSID50412119; AKOS030255688; FT-0662880; FT-0662881; FT-0662991; 4 inverted exclamation mark -Benzyloxy Carvedilol
|
|
CAS | 887352-95-6 | |
PubChem CID | 5235392 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 512.6 | ALogp: | 5.7 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 13 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 85.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 38 | QED Weighted: | 0.179 |
Caco-2 Permeability: | -5.683 | MDCK Permeability: | 0.00001190 |
Pgp-inhibitor: | 0.978 | Pgp-substrate: | 0.988 |
Human Intestinal Absorption (HIA): | 0.038 | 20% Bioavailability (F20%): | 0.962 |
30% Bioavailability (F30%): | 0.858 |
Blood-Brain-Barrier Penetration (BBB): | 0.489 | Plasma Protein Binding (PPB): | 98.43% |
Volume Distribution (VD): | 0.938 | Fu: | 0.55% |
CYP1A2-inhibitor: | 0.917 | CYP1A2-substrate: | 0.894 |
CYP2C19-inhibitor: | 0.879 | CYP2C19-substrate: | 0.638 |
CYP2C9-inhibitor: | 0.306 | CYP2C9-substrate: | 0.827 |
CYP2D6-inhibitor: | 0.971 | CYP2D6-substrate: | 0.954 |
CYP3A4-inhibitor: | 0.958 | CYP3A4-substrate: | 0.903 |
Clearance (CL): | 9.154 | Half-life (T1/2): | 0.221 |
hERG Blockers: | 0.959 | Human Hepatotoxicity (H-HT): | 0.895 |
Drug-inuced Liver Injury (DILI): | 0.057 | AMES Toxicity: | 0.592 |
Rat Oral Acute Toxicity: | 0.019 | Maximum Recommended Daily Dose: | 0.917 |
Skin Sensitization: | 0.932 | Carcinogencity: | 0.507 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.806 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000697 | 0.446 | D0W9LX | 0.739 | ||||
ENC001018 | 0.346 | D0J2KV | 0.405 | ||||
ENC005604 | 0.343 | D01SAT | 0.386 | ||||
ENC005603 | 0.343 | D04DKH | 0.368 | ||||
ENC001446 | 0.336 | D0H5LK | 0.346 | ||||
ENC005492 | 0.333 | D0D0YM | 0.343 | ||||
ENC001109 | 0.315 | D08QIP | 0.337 | ||||
ENC004355 | 0.309 | D05MBZ | 0.329 | ||||
ENC004354 | 0.309 | D02CTS | 0.326 | ||||
ENC003208 | 0.308 | D0H5MB | 0.317 |